Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea. Materials and methods: Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively. Results: Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020). Conclusion: This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.
Abstract
Purpose: Acute promyelocytic leukemia (APL) is a rare disease in children and there are some different characteristics between children and adult. We aimed to evaluate incidence, clinical characteristics and treatment outcomes of pediatric APL in Korea. Materials and methods: Seventy-nine pediatric APL patients diagnosed from January 2009 to December 2016 in 16 tertiary medical centers in Korea were reviewed retrospectively. Results: Of 801 acute myeloid leukemia children, 79 (9.9%) were diagnosed with APL. The median age at diagnosis was 10.6 years (range, 1.3 to 18.0). Male and female ratio was 1:0.93. Thirty patients (38.0%) had white blood cell (WBC) count greater than 10×109/L at diagnosis. All patients received induction therapy consisting of all-trans retinoic acid and chemotherapy. Five patients (6.6%) died during induction chemotherapy and 66 patients (86.8%) achieved complete remission (CR) after induction chemotherapy. The causes of death were three intracranial hemorrhage, one cerebral infarction, and one sepsis. Five patients (7.1%) suffered a relapse during or after maintenance chemotherapy. The estimated 4-year event-free survival and overall survival (OS) rates were 82.1%±4.4%, 89.7%±5.1%, respectively. The 4-year OS was significantly higher in patients with initial WBC < 10×109/L than in those with initial WBC ≥ 10×109/L (p=0.020). Conclusion: This study showed that the CR rates and survival outcomes in Korean pediatric APL patients were relatively good. The initial WBC count was the most important prognostic factor and most causes of death were related to serious bleeding in the early stage of treatment.
참고문헌 (21)
- Mantadakis E, "A comprehensive review of acute promyelocytic leukemia in children", Acta Haematol, 119, pp.73~82 (2008)
- Kutny MA, "Treatment of paediatric APL : how does the therapeutic approach differ from adults?", Best Pract Res Clin Haematol, 27, pp.69~78 (2014)
- 유은선, "Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia", Clinical and Experimental Pediatrics, 54(3), pp.95~104 (2011), 대한소아청소년과학회
- Jastaniah W, "Clinical characteristics and outcome of childhood acute promyelocitic leukemia(APL)in Saudi Arabia : a multicenter SAPHOS leukemia group study", Hematology, 23, pp.316~323 (2018)
- Thomas X, "Acute promyelocytic leukemia: a history over 60 years. From the most malignant to the most curable form of acute leukemia", Oncol Ther, 7, pp.33~65 (2019)
- de Botton S, "Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy", J Clin Oncol, 22, pp.1404~1412 (2004)
- Ortega JJ, "Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia : a multicenter study by the PETHEMA Group", J Clin Oncol, 23, pp.7632~7640 (2005)
- Bally C, "Outcome of acute promyelocytic leukemia(APL)in children and adolescents : an analysis in two consecutive trials of the European APL Group", J Clin Oncol, 30, pp.1641~1646 (2012)
- Testi AM, "GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia(APL)in children", Blood, 106, pp.447~453 (2005)
- Testi AM, "Acute promyelocytic leukemia(APL) : comparison between children and adults", Mediterr J Hematol Infect Dis, 6, pp.e2014032~ (2014)
- Abla O, "How I treat children and adolescents with acute promyelocytic leukaemia", Br J Haematol, 164, pp.24~38 (2014)
- Sanz MA, "Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia : a joint study of the PETHEMA and GIMEMA cooperative groups", Blood, 96, pp.1247~1253 (2000)
- Myoung-Hyun Kim, "Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol", Blood Research, 45(4), pp.236~241 (2010), 대한혈액학회
- Testi AM, "Risk-adapted treatment of acute promyelocytic leukemia : results from the International Consortium for Childhood APL", Blood, 132, pp.405~412 (2018)
- Rajpurkar M, "Risk markers for significant bleeding and thrombosis in pediatric acute promyelocytic leukemia : report from the Children’s Oncology Group Study AAML0631", J Pediatr Hematol Oncol, 41, pp.51~55 (2019)
- Sanz MA, "Open issues on bleeding and thrombosis in acute promyelocytic leukemia", Thromb Res, 125(Suppl 2), pp.S51~S54 (2010)
- Castaigne S, "Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid(25 mg", m2)in acute promyelocytic leukemia, 1993, pp.82, 3560~3563
- Creutzig U, "Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses", Br J Haematol, 149, pp.399~409 (2010)
- Kutny MA, "Arsenic trioxide consolidation allows anthracycline dose reduction for pediatric patients with acute promyelocytic leukemia : report from the Children’s Oncology Group Phase III Historically Controlled Trial AAML0631", J Clin Oncol, 35, pp.3021~3029 (2017)
- Douer D, "All-trans retinoic acid and late relapses in acute promyelocytic leukemia : very long-term follow-up of the North American Intergroup Study I0129", Leuk Res, 37, pp.795~801 (2013)
- Dvorak CC, "Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia", Biol Blood Marrow Transplant, 14, pp.824~830 (2008)